Background:To determine patient-reported vision-related quality of life(VR-QoL)following Boston type I keratoprosthesis(BI-KPro)surgery and its association with postoperative best-corrected visual acuity(BCVA).Methods...Background:To determine patient-reported vision-related quality of life(VR-QoL)following Boston type I keratoprosthesis(BI-KPro)surgery and its association with postoperative best-corrected visual acuity(BCVA).Methods:Descriptive cross-sectional study.Consecutive consenting patients with BI-KPro were included.The French National Eye Institute Visual Function Questionnaire-25 administered at 51±18 months postoperatively measured VR-QoL.Clinical charts were reviewed for demographics,indications for BI-KPro,baseline and postoperative(at time of interview)BCVA.For patients operated unilaterally,stratification of VR-QoL scores based on BCVA in the non-operated eye was performed.Multivariate linear regression was carried out,using VR-QoL scores as dependent variables,and demographics and postoperative BCVA as covariates.For patients operated bilaterally,Spearman correlation between VR-QoL scores and BCVA was performed.P<0.05 indicated statistical significance.Results:Sixty-four patients,aged 59±14 years,52%male,with a follow-up of 54±19 months,were included.Postoperative BCVA increased from baseline in all operated eyes(P=0.000).In patients with unilateral BI-KPro(n=52),the VR-QoL overall score was 70.7±25.1.Scores on all questionnaire subscales were greater when BCVA in the non-operated eye was>20/200 compared to 20/200(P=0.000).BCVA in the non-operated eye was positively associated with all subscales(P<0.01)independently of age,sex,follow-up duration and postoperative BCVA in the operated eye.In patients with bilateral BI-KPro(n=12)the VR-QoL overall score was 63.0±18.7.BCVA in the best eye positively correlated with Near/Distance activities,and social functioning subscales(P<0.05).There was no significant difference between VR-QoL scores of patients operated unilaterally vs.bilaterally.Conclusions:We describe VR-QoL more than 4 years after BI-KPro surgery.Compared to data at 1 year previously reported,our results suggest that,as vision progressively deteriorates in the operated eye,patients increasingly rely on their non-operated eye.VR-QoL after bilateral BI-KPro is assessed for the first time,and appears comparable to that after unilateral surgery.Larger,prospective,long-term studies,with assessment at baseline,are warranted.展开更多
· AIM: To investigate the visual function and the relationship with vision-related quality of life(VRQOL)after macular hole repair surgery.· METHODS: Prospective case series. Thirty-six consecutive eyes in 3...· AIM: To investigate the visual function and the relationship with vision-related quality of life(VRQOL)after macular hole repair surgery.· METHODS: Prospective case series. Thirty-six consecutive eyes in 36 patients who underwent pars plana vitrectomy(PPV) and internal limiting membrane(ILM) peeling were included. The 25-item National Eye Institute Visual Function Questionnaire(VFQ-25) was answered by the participants before and 3 and 12 mo after operation. Follow-up visits examinations included best-corrected visual acuity(BCVA), clinical examination,and central macular thickness(CMT) measured by optical coherence tomography(OCT).·RESULTS: Macular-hole closure was achieved in 35 of36 eyes(97.2%). At baseline and months 3 and 12, the log MAR BCVAs(mean±SD) were 1.15±0.47, 0.68±0.53(P 【0.0001 versus baseline), and 0.55 ±0.49(P 【0.001 versus baseline, P =0.273 versus month 3), respectively; the CMTs(μm) were 330 ±81, 244 ±62(P 【0.001 versus baseline), and 225±58(P 【0.001 versus baseline, P =0.222 versus month 3), respectively; the median preoperative VFQ-25 composite score of 73.50(63.92-81.13) increased postoperatively to 85.50(80.04-89.63) at 3mo(P 【0.001)and 86.73(82.50-89.63) at 12mo(P 【0.001) respectively.The improved BCVA was correlated with improvements in five subscales(r =-0.605 to-0.336, P 【0.001 to P =0.046) at 12 mo.· CONCLUSION: PPV with ILM peeling improved anatomic outcome, visual function, and VRQOL. Theimproved BCVA was an important factor related to the improved VRQOL.展开更多
目的探讨斜弱视生存质量量表(Amblyopia and Strabismus Questionnaire,A&SQ)在成人斜弱视患者术前生存质量状况评估中的最佳临界值。方法对214例住院成人斜弱视患者,在入院第1天采用A&SQ、国家眼科研究视功能量表(NEI-VFQ-25)...目的探讨斜弱视生存质量量表(Amblyopia and Strabismus Questionnaire,A&SQ)在成人斜弱视患者术前生存质量状况评估中的最佳临界值。方法对214例住院成人斜弱视患者,在入院第1天采用A&SQ、国家眼科研究视功能量表(NEI-VFQ-25)进行调查,以NEI-VFQ-25作为诊断"金标准"。结果 A&SQ量表得分与NEI-VFQ-25量表得分呈正相关(r=0.666,P<0.01);以NEI-VFQ-25作为诊断"金标准",A&SQ量表最佳临界值为71.5分,灵敏度、特异度分别为0.844和0.980,曲线下面积为0.938(P<0.01)。由于量表采用Likert 5级评分,临界值取为整数71分。结论 A&SQ量表在成人斜弱视患者术前生存质量状况评估中的最佳临界值为71分,是成人斜弱视患者术前生存质量状况测评的有效工具。展开更多
目的:探讨升阳养血汤在干眼病患者中的应用。方法:选择2018年8月-2019年8月于本院治疗的78例干眼病患者,采用盲抽法分为观察组和对照组各39例。对照组采用玻璃酸钠滴眼液治疗,观察组在对照组基础上加用升阳养血汤治疗。比较两组临床疗...目的:探讨升阳养血汤在干眼病患者中的应用。方法:选择2018年8月-2019年8月于本院治疗的78例干眼病患者,采用盲抽法分为观察组和对照组各39例。对照组采用玻璃酸钠滴眼液治疗,观察组在对照组基础上加用升阳养血汤治疗。比较两组临床疗效、临床症状积分、泪液分泌量、视觉功能相关生活质量量表评分(National Eye Institute Visual Function Questionnaire-25,NEI-VFQ-25)。结果:观察组临床总有效率较对照组高,差异有统计学意义(P<0.05)。治疗后,两组眼干涩、烧灼感、异物感与总积分均降低;且与对照组相比,观察组症状积分较低,差异有统计学意义(P<0.05)。治疗2周后,两组患者泪液分泌量均较治疗前多;且观察组多于对照组,差异有统计学意义(P<0.05)。治疗2周后,与对照组相比,观察组NEIVFQ-25评分高,差异有统计学意义(P<0.05)。结论:升阳养血汤治疗干眼病效果显著,可改善临床症状,促进泪液分泌,提高患者生活质量,值得临床推广应用。展开更多
Background：Age-related macular degeneration （AMD） is the leading cause of irreversible vision loss among the older population.In China,treatment of age-related ocular diseases is becoming a priority in eye care ser...Background：Age-related macular degeneration （AMD） is the leading cause of irreversible vision loss among the older population.In China,treatment of age-related ocular diseases is becoming a priority in eye care services.This study was to investigate the clinical characteristics and quality of life of Chinese patients with wet AMD and current treatment types,to evaluate short-term gains in different treatments,and to investigate associations between visual function and vision-related quality of life （VRQoL）.Methods：A prospective,observational,noninterventional study was conducted.Basic data were collected from patients with clinical diagnoses of wet AMD before clinical assessments at baseline.VRQoL was measured with the Chinese version of the National Eye Institute Visual Function Questionnaire-25 （NEI VFQ-25）.Correlations of the NEI VFQ-25 subscale scores with best-corrected visual acuity （BCVA） and between-group differences were analyzed.Results：A total of 80 wet AMD patients were enrolled,with the mean age of 68.40 years.About one-quarter ofwetAMD patients received intravitreal （IVT） ranibizumab treatment,and 67％ of them were treated on apro re nata basis.The visual acuity of patients treated with IVT ranibizumab at month 3 after treatment was significantly increased,whereas patients treated with traditional Chinese medicine achieved no significant improvement.Cronbach＇s α for the NEI VFQ-25 subscales ranged from 0.697 to 0.843.Eight subscale and overall composite scores were moderately correlated with the BCVA of the better-seeing eye.Significant differences in the overall NEI VFQ-25 scores and other subscales were observed between patients with BCVA in the better-seeing eye of less than 50 letters and the others.Conclusions：Patients treated with IVT ranibizumab experienced better vision improvement at short-term follow-up.The Chinese version of the NEI VFQ-25 is a valid and reliable tool for assessing the VRQoL of Chinese wet AMD patients.展开更多
文摘Background:To determine patient-reported vision-related quality of life(VR-QoL)following Boston type I keratoprosthesis(BI-KPro)surgery and its association with postoperative best-corrected visual acuity(BCVA).Methods:Descriptive cross-sectional study.Consecutive consenting patients with BI-KPro were included.The French National Eye Institute Visual Function Questionnaire-25 administered at 51±18 months postoperatively measured VR-QoL.Clinical charts were reviewed for demographics,indications for BI-KPro,baseline and postoperative(at time of interview)BCVA.For patients operated unilaterally,stratification of VR-QoL scores based on BCVA in the non-operated eye was performed.Multivariate linear regression was carried out,using VR-QoL scores as dependent variables,and demographics and postoperative BCVA as covariates.For patients operated bilaterally,Spearman correlation between VR-QoL scores and BCVA was performed.P<0.05 indicated statistical significance.Results:Sixty-four patients,aged 59±14 years,52%male,with a follow-up of 54±19 months,were included.Postoperative BCVA increased from baseline in all operated eyes(P=0.000).In patients with unilateral BI-KPro(n=52),the VR-QoL overall score was 70.7±25.1.Scores on all questionnaire subscales were greater when BCVA in the non-operated eye was>20/200 compared to 20/200(P=0.000).BCVA in the non-operated eye was positively associated with all subscales(P<0.01)independently of age,sex,follow-up duration and postoperative BCVA in the operated eye.In patients with bilateral BI-KPro(n=12)the VR-QoL overall score was 63.0±18.7.BCVA in the best eye positively correlated with Near/Distance activities,and social functioning subscales(P<0.05).There was no significant difference between VR-QoL scores of patients operated unilaterally vs.bilaterally.Conclusions:We describe VR-QoL more than 4 years after BI-KPro surgery.Compared to data at 1 year previously reported,our results suggest that,as vision progressively deteriorates in the operated eye,patients increasingly rely on their non-operated eye.VR-QoL after bilateral BI-KPro is assessed for the first time,and appears comparable to that after unilateral surgery.Larger,prospective,long-term studies,with assessment at baseline,are warranted.
文摘· AIM: To investigate the visual function and the relationship with vision-related quality of life(VRQOL)after macular hole repair surgery.· METHODS: Prospective case series. Thirty-six consecutive eyes in 36 patients who underwent pars plana vitrectomy(PPV) and internal limiting membrane(ILM) peeling were included. The 25-item National Eye Institute Visual Function Questionnaire(VFQ-25) was answered by the participants before and 3 and 12 mo after operation. Follow-up visits examinations included best-corrected visual acuity(BCVA), clinical examination,and central macular thickness(CMT) measured by optical coherence tomography(OCT).·RESULTS: Macular-hole closure was achieved in 35 of36 eyes(97.2%). At baseline and months 3 and 12, the log MAR BCVAs(mean±SD) were 1.15±0.47, 0.68±0.53(P 【0.0001 versus baseline), and 0.55 ±0.49(P 【0.001 versus baseline, P =0.273 versus month 3), respectively; the CMTs(μm) were 330 ±81, 244 ±62(P 【0.001 versus baseline), and 225±58(P 【0.001 versus baseline, P =0.222 versus month 3), respectively; the median preoperative VFQ-25 composite score of 73.50(63.92-81.13) increased postoperatively to 85.50(80.04-89.63) at 3mo(P 【0.001)and 86.73(82.50-89.63) at 12mo(P 【0.001) respectively.The improved BCVA was correlated with improvements in five subscales(r =-0.605 to-0.336, P 【0.001 to P =0.046) at 12 mo.· CONCLUSION: PPV with ILM peeling improved anatomic outcome, visual function, and VRQOL. Theimproved BCVA was an important factor related to the improved VRQOL.
文摘目的:探讨升阳养血汤在干眼病患者中的应用。方法:选择2018年8月-2019年8月于本院治疗的78例干眼病患者,采用盲抽法分为观察组和对照组各39例。对照组采用玻璃酸钠滴眼液治疗,观察组在对照组基础上加用升阳养血汤治疗。比较两组临床疗效、临床症状积分、泪液分泌量、视觉功能相关生活质量量表评分(National Eye Institute Visual Function Questionnaire-25,NEI-VFQ-25)。结果:观察组临床总有效率较对照组高,差异有统计学意义(P<0.05)。治疗后,两组眼干涩、烧灼感、异物感与总积分均降低;且与对照组相比,观察组症状积分较低,差异有统计学意义(P<0.05)。治疗2周后,两组患者泪液分泌量均较治疗前多;且观察组多于对照组,差异有统计学意义(P<0.05)。治疗2周后,与对照组相比,观察组NEIVFQ-25评分高,差异有统计学意义(P<0.05)。结论:升阳养血汤治疗干眼病效果显著,可改善临床症状,促进泪液分泌,提高患者生活质量,值得临床推广应用。
文摘Background：Age-related macular degeneration （AMD） is the leading cause of irreversible vision loss among the older population.In China,treatment of age-related ocular diseases is becoming a priority in eye care services.This study was to investigate the clinical characteristics and quality of life of Chinese patients with wet AMD and current treatment types,to evaluate short-term gains in different treatments,and to investigate associations between visual function and vision-related quality of life （VRQoL）.Methods：A prospective,observational,noninterventional study was conducted.Basic data were collected from patients with clinical diagnoses of wet AMD before clinical assessments at baseline.VRQoL was measured with the Chinese version of the National Eye Institute Visual Function Questionnaire-25 （NEI VFQ-25）.Correlations of the NEI VFQ-25 subscale scores with best-corrected visual acuity （BCVA） and between-group differences were analyzed.Results：A total of 80 wet AMD patients were enrolled,with the mean age of 68.40 years.About one-quarter ofwetAMD patients received intravitreal （IVT） ranibizumab treatment,and 67％ of them were treated on apro re nata basis.The visual acuity of patients treated with IVT ranibizumab at month 3 after treatment was significantly increased,whereas patients treated with traditional Chinese medicine achieved no significant improvement.Cronbach＇s α for the NEI VFQ-25 subscales ranged from 0.697 to 0.843.Eight subscale and overall composite scores were moderately correlated with the BCVA of the better-seeing eye.Significant differences in the overall NEI VFQ-25 scores and other subscales were observed between patients with BCVA in the better-seeing eye of less than 50 letters and the others.Conclusions：Patients treated with IVT ranibizumab experienced better vision improvement at short-term follow-up.The Chinese version of the NEI VFQ-25 is a valid and reliable tool for assessing the VRQoL of Chinese wet AMD patients.
